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A 9-month-old infant died from Ebola virus (EBOV) disease 
with unknown epidemiological link. While her parents did not 
report previous illness, laboratory investigations revealed per-
sisting EBOV RNA in the mother’s breast milk and the father’s 
seminal fluid. Genomic analysis strongly suggests EBOV trans-
mission to the child through breastfeeding.
Keywords. Ebola virus; mother-to-child transmission; 
real-time sequencing; breast milk; asymptomatic carriage.
 
On 18 August 2015, a 9-month-old breastfed female infant 
from Dubréka, Guinea, developed fever (38°C), diarrhea, 
vomiting, and cough. The father, a trained nurse, adminis-
tered erythromycin, paracetamol (acetaminophen), amo-
diaquine, albendazole, and metopimazine. During the 
following 5 days, the clinical status of the child remained 
relatively stable. On 24 August, her condition rapidly dete-
riorated, with severe vomiting and diarrhea. The family 
attended a primary healthcare center in Dubréka, which 
referred them to the University Hospital in Conakry. On 
the way to the hospital, the infant developed respira-
tory distress and died. A  buccal swab tested positive for 
Ebola virus (EBOV) by reverse transcription polymer-
ase chain reaction (RT-PCR) on 25 August (Figure  1A). 
The National Committee of Ethics in Medical Research 
of Guinea approved the use of diagnostic leftover sam-
ples and corresponding patient data for this study (permit 
number 11/CNERS/14). All necessary consents required 
by applicable law from the patients whose information is 
included in the article have been obtained in writing.
An epidemiological investigation did not yield a known 
source of infection. Contact with known Ebola virus disease 
(EVD) patients or survivors could not be identified. The child 
was the first EVD case in >42 days in the area where the family 
was living (Supplementary Figure 1). She had never presented at 
a healthcare facility and did not receive routine vaccinations, as 
the mother feared contact with EVD patients in health centers. 
In addition, the family members reported few social contacts 
with the exception of contacts to the 4-year-old stepbrother and 
the grandmother.
In an attempt to trace the source of infection by molecular epi-
demiology, the EBOV-positive RNA of the child was transferred 
to our sequencing facility at the Ebola Treatment Center in Coyah 
on 30 August and the viral genome was sequenced using MinION 
technology in Guinea (Oxford Nanopore, United Kingdom) [1]. 
Phylogenetic analysis revealed that the virus (European Nucleotide 
Archive [ENA] accession number LT630606) belonged to the 
Sierra-Leone 3 (SL3) lineage and clustered with strains of the large 
Conakry–Dubréka sublineage that were circulating between May 
and July 2015 in these prefectures (Figure 1B) [1]. We identified 
a unique genomic signature consisting of 3 nucleotide polymor-
phisms at positions 6027, 12290, and 15660, which were not found 
elsewhere in the EBOV database.
Due to EVD confirmation in the child, the parents received 
the recombinant vesicular stomatitis virus (rVSV)-based 
vaccine expressing the glycoprotein of Zaire Ebola virus 
(rVSV-ZEBOV) vaccine on 27 August (Figure 1A) [2]. On 30 
August, both tested positive for EBOV-specific immunoglob-
ulin G but not immunoglobulin M in enzyme-linked immu-
nosorbent assay, which was interpreted as a sign of past EBOV 
infection and raised the suspicion of asymptomatic virus 
carriage. Therefore, body fluids of the parents were tested for 
EBOV RNA using the RealStar ZEBOV RT-PCR kit (Altona, 
Germany) on a Rotor-Gene instrument (Qiagen) [3]. On 9 
B R I E F  R E P O R T
Received 5 July 2016; editorial decision 11 November 2016; accepted 30 November 2016.
Correspondence: S. Duraffour, Bernhard-Nocht-Institute for Tropical Medicine, Bernhard- 
Nocht-Str. 74, 20359 Hamburg, Germany (sophieduraffour@yahoo.fr).
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society 
of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the 
work, in any medium, provided the original work is not altered or transformed in any way, and 
that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
DOI: 10.1093/cid/ciw793
 Clinical Infectious Diseases Advance Access published January 6, 2017
 at U
niversity of Birm
ingham
 on January 18, 2017
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
2 • CID 2016:XX (XX XXXX) • BRIEF REPORT
September, the mother’s breast milk tested EBOV RNA pos-
itive with a cycle threshold (Ct) value of 23.3, whereas urine 
and whole blood were negative (Figure 1A). Sequencing and 
phylogenetic analysis demonstrated that the viruses from child 
and breast milk (ENA accession number LT630561) are closely 
related and share 2 of the unique single-nucleotide polymor-
phisms (Figure  1B). In the phylogenetic tree, the virus from 
the breast milk appears ancestral to that of the infant. On 
15 September, a semen sample from the father tested EBOV 
RNA positive with a Ct value of 35.6, whereas urine and whole 
blood were negative (Figure 1A). The presence of EBOV RNA 
in the semen sample was confirmed by repeat RNA extraction 
and RT-PCR testing as well as genomic sequencing. The virus 
sequenced from the semen (ENA accession number LT630562) 
was also part of the SL3 lineage, but ancestral to the Conakry–
Dubréka cluster and without close link to the viruses of mother 
and child (Figure 1B). On 7 October, the father’s semen tested 
negative for EBOV.
Epidemiological investigation could not reveal source, local-
ity, or time period of EBOV infection in the parents. They 
did not report a severe febrile illness and denied contact with 
known EVD cases or family deaths, or attending funerals since 
the beginning of the Ebola outbreak. The father, a 28-year-old 
nurse, had worked as community healthcare worker in the 
district of Mali in the northern part of Guinea from February 
2014 to March 2015. Only 5 EVD cases have been reported in 
this district throughout the outbreak. From March to August 
2015, he was unemployed and lived in Dubréka in a family with 
4 members. With the exception of a motorcycle accident that 
required dental reconstructive surgery in a private clinic in 
Conakry, he denied any noticeable health episode in the past. 
The mother, a 23-year-old college student, did not report any 
Figure 1. Timeline of clinical events, interventions, and laboratory investigations and phylogenetic tree of the Ebola virus sublineage containing the sequences from the 
family. A, The 3 cases are depicted by horizontal bars with events indicated by arrows. Results of laboratory investigations are indicated as positive (+) and negative (−). For 
positive real-time polymerase chain reaction results, the cycle threshold is given, which is an indirect measure of viral RNA concentration. B, Phylogenetic reconstruction 
was performed by maximum likelihood under the GTR + Gamma model using RAxML as described [1, 12]. The subtree shown in the figure depicts the sequences that share 
a common ancestor with the sequences from the mother and father; the complete tree is shown in [1]. The geographic origin of the cases is indicated by color. European 
Nucleotide Archive accession numbers are LT630562 for the father’s semen, LT630561 for the mother’s breast milk, and LT630605 for the child’s swab. The length of the 
branches roughly corresponds to the number of single-nucleotide polymorphisms in the respective strain(s) that distinguish them from the ancestral virus. Abbreviations: Ct, 
cycle threshold; EBOV, Ebola virus; IgG, immunoglobulin G; IgM, immunoglobulin M; rVSV-ZEBOV, recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the 
glycoprotein of Zaire Ebola virus; SNP, single-nucleotide polymorphism.
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medical episode except chronic headaches. She traveled daily 
between Dubréka and her school in Conakry by collective taxi.
The described family cluster highlights peculiarities of EVD, 
which are poorly understood and difficult to study, including 
EBOV infection in the absence of classical risk factors and virus 
persistence in patients with a mild or asymptomatic course of 
EVD associated with risk of virus transmission.
The molecular epidemiological data indicate that mother and 
father became infected in Conakry or Dubréka and that both 
infections are not directly linked. The lack of known risk factors 
suggests that sources and routes of transmission exist, which 
are not yet understood. The signs and symptoms of EVD in the 
parents are also difficult to assess, as intermittent febrile illness 
may be considered the norm in rural populations in Africa. 
In the absence of objective clinical investigations, we describe 
the disease here as “mild or asymptomatic.” Whether there is 
an association between this specific clinical manifestation and 
the (unknown) source and route of infection is a matter of 
speculation.
Mild or asymptomatic EBOV infections have been described 
[4]. However, it is not known whether this clinical manifesta-
tion, like severe nonfatal EVD, is associated with virus persis-
tence [5, 6]. The cases of mother and father show that EBOV 
may persist in breast milk and seminal fluid in survivors with 
mild disease or asymptomatic infection. This raises the possibil-
ity of virus transmission by individuals who were not diagnosed 
with the disease (and thus do not know they had EVD) and are 
not listed in the national survivors databases, like the 2 parents.
The closely related EBOV sequences in mother and child, the 
ancestral position of the mother’s virus relative to the child’s 
virus in the phylogram, the epidemiological link between 
mother and child, and the absence of contact of the child to 
other EVD cases in the community or the hospital suggest that 
the mother transmitted the virus to the child via breastfeed-
ing. Our findings are in line with the case of an asymptomatic 
mother whose breast milk tested positive and who may have 
transmitted EBOV to her 13-month-old child [7]. In addi-
tion, there are anecdotal descriptions on presence of EBOV or 
Sudan virus RNA in breast milk of mothers with symptomatic 
EVD [8, 9]. The timing of events in our case remains specula-
tive. Given that the child was breastfed for 9 months before she 
became infected, it is plausible to assume that the infection in 
the mother occurred rather recently before the child’s infection. 
However, due to the mild or asymptomatic course, the accumu-
lation of EBOV in the mammary gland may have been delayed 
relative to blood.
The detection of EBOV RNA in seminal fluid of the father 
suggests that the number of survivors with persisting EBOV 
in seminal fluid, as predicted from the incidence of hospital-
ized cases only [10], may be an underestimate. The mecha-
nisms of EBOV persistence in immunologically privileged or 
glandular tissue, in particular in the presence of circulating 
antibodies against EBOV, are not well understood [5, 11]. 
The cases described here at least suggest a lack of correlation 
between severity of disease and virus persistence. Whether 
persistence is associated with reduced levels of neutralizing 
antibodies or poor T-cell memory response remains to be 
studied.
In conclusion, the described findings call for efforts to 
estimate the prevalence of EVD survivors who had not been 
diagnosed during the acute phase and improve counseling 
for this group of survivors. Fortunately, transmission of virus 
via breastfeeding many months after recovery is likely to be 
an extremely rare phenomenon. Among the high number of 
female survivors, there are presumably hundreds of mothers 
who have given birth and nursed healthy babies in the postout-
break period.
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